Management of atrial fibrillation

Australian Family Physician

Volumn 36, Issue 7, 2007, Pages 506-511

  Kistler, Peter M ^a,b   Habersberger, Jonathon ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG CONTRAINDICATION; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HUMAN;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; ELECTROCARDIOGRAPHY; HUMANS;

EID: 34547764853     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Stewart S, Hart C, Hole D, et al. A population based study of the long term risks associated with atrial fibrillation: 20 year follow up of the Renfrew/ Paisley study. Am J Med 2002;113:359-64.
2. Hart R, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
3. Hart R, Halperin J. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32:803-8.
4. Fuster V, Smith S, Priori S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation.
5. van Gelder I, Isabelle C, Hagens V. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
6. Weerisooriya R, Davis M, Powell A. The Australian Intervention Randomised Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003;41:1697-702.
7. Khan I, Mehta N, Gowda R. Amiodarone for pharmacological cardioversion of recent onset atrial fibrillation. Int J Cardiol 2003;89:239-48.
8. Kochiadakis G, Igoumendis N, Marketou M, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000;84:251-7.
9. Anderson J, Gilbert E, Alpert B, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicentre, double blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-70.
10. Hohnloser S, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacological conversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-8.
11. van Gelder I, Tuinenburg A, Schoonderwoerd B, et al. Pharmacologic versus direct current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol 1999;84:147R-51.
12. Cappato R, Calkins H, Chen S, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-5.